Sage Financial Management Group Inc. buys 757 shares of Johnson & Johnson (NYSE:JNJ)


Sage Financial Management Group Inc. increased its position in Johnson & Johnson (NYSE:JNJGet a rating) by 40.3% during the first quarter, Holdings Channel.com reports. The company held 2,635 shares of the company after purchasing an additional 757 shares during the quarter. Johnson & Johnson accounts for about 0.3% of Sage Financial Management Group Inc.’s holdings, making the stock its 23rd-largest position. Sage Financial Management Group Inc.’s holdings in Johnson & Johnson were worth $467,000 at the end of the most recent period.

A number of other major investors have also recently changed their holdings in JNJ. Norges Bank bought a new position in Johnson & Johnson stock in Q4 worth $4,172,929,000. BlackRock Inc. increased its holdings of Johnson & Johnson shares by 2.6% in the fourth quarter. BlackRock Inc. now owns 200,021,352 shares of the company worth $34,217,654,000 after purchasing an additional 4,982,885 shares in the last quarter. GQG Partners LLC increased its equity stake in Johnson & Johnson by 1,109.4% in Q4. GQG Partners LLC now owns 3,954,383 shares of the company worth $676,375,000 after purchasing an additional 3,627,424 shares last quarter. State Street Corp raised its position in Johnson & Johnson by 1.8% in the fourth quarter. State Street Corp now owns 144,677,639 shares of the company valued at $24,750,004,000 after purchasing an additional 2,492,359 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new stake in Johnson & Johnson in Q4 valued at $269,447,000. 68.78% of the shares are currently held by institutional investors.

Analyst upgrades and downgrades

A number of equity research analysts have recently commented on the company. Citigroup lowered its price target on Johnson & Johnson from $205.00 to $201.00 in a research report Wednesday. Goldman Sachs Group raised its price target on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a Tuesday, April 12 research report. Wells Fargo & Company raised its price target on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a Wednesday, July 13 research report. Raymond James raised his price target on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a Wednesday, April 20 research report. To finish, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong buy” rating in a Tuesday, May 17 research report. Four investment analysts gave the stock a hold rating, six gave the company a buy rating and one gave the company a high buy rating. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $189.89.

Johnson & Johnson Stock up 0.5%

JNJ Stock opened at $172.12 on Friday. The company has a debt ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. The company has a market capitalization of $452.92 billion, a price/earnings ratio of 25.05, a PEG ratio of 3.48 and a beta of 0.63. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The stock has a fifty-day moving average of $176.25 and a 200-day moving average of $174.35.

Johnson & Johnson (NYSE:JNJGet a rating) last released its quarterly results on Tuesday, July 19. The company reported earnings per share of $2.59 for the quarter, beating the consensus estimate of $2.57 by $0.02. The company posted revenue of $24.02 billion in the quarter, versus a consensus estimate of $23.85 billion. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The company’s quarterly revenue increased 3.0% from the same quarter last year. In the same quarter of the previous year, the company achieved EPS of $2.48. As a group, equity research analysts expect Johnson & Johnson to post earnings per share of 10.02 for the current year.

Johnson & Johnson announces dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Tuesday, August 23 will receive a dividend of $1.13. The ex-date of this dividend is Monday, August 22. This represents an annualized dividend of $4.52 and a yield of 2.63%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Insiders place their bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the company in a transaction dated Friday, June 10. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company, valued at approximately $12,336,803. The sale was disclosed in a filing with the SEC, accessible via the SEC website. In other news, CAO Robert J. Decker sold 8,462 Johnson & Johnson shares in a trade dated Thursday, May 26. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares of the company, valued at approximately $2,785,140. The sale was disclosed in a filing with the SEC, accessible via this hyperlink. Additionally, Executive Vice President Kathryn E. Wengel sold 40,000 Johnson & Johnson shares in a trade dated Friday, June 10. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares of the company, valued at approximately $12,336,803. Disclosure of this sale can be found here. 0.35% of the shares are held by insiders.

About Johnson & Johnson

(Get a rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.

See also

Want to see what other hedge funds own JNJ? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJGet a rating).

Institutional ownership by quarter for Johnson & Johnson (NYSE: JNJ)



Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.

Geraldine L. Melton